Cerdulatinib

Cerdulatinib is an orally bioavailable dual inhibitor of spleen tyrosine kinase (Syk) and Janus-associated kinases (JAK), with potential anti-inflammatory and antineoplastic activity. Upon oral administration, cerdulatinib specifically binds to and inhibits the activity of Syk, JAK1, and JAK3 with preferential inhibition of JAK1 and JAK3-dependent cytokine-mediated signaling and functional responses. This negatively affects the downstream JAK-STAT (signal transducer and activator of transcription) pathway, and leads to both reduced inflammation in various animal models and enhanced antiproliferative activity towards non-Hodgkin’s lymphoma (NHL) cell lines. Syk is a non-receptor cytoplasmic tyrosine kinase involved in signal transduction in cells of hematopoietic origin including B cells, macrophages, basophils and neutrophils. Abnormal function of Syk has been implicated in several hematopoietic malignancies including NHL and chronic lymphocytic leukemia (CLL). It is grouped under the following drug class(es): JAK inhibitors. The directory classifies it as a under development API with a synthetic source/manufacturing origin. Other names for this substance include cerdulatinibum and 4-(cyclopropylamino)-2-(4-(4-ethylsulfonylpiperazin-1-yl)anilino)pyrimidine-5-carboxamide. Its PubChem CID is 44595079.